AAFMAA Wealth Management & Trust LLC Sells 852 Shares of Stryker Corporation $SYK

Key Points

• AAFMAA Wealth Management & Trust LLC decreased its stake in Stryker Corporation by 15.5%, selling 852 shares and holding 4,634 shares valued at approximately $1.83 million.
• Director Ronda E. Stryker sold 200,000 shares of Stryker stock for about $75.29 million, representing a 5.84% decrease in their ownership, while the stock price was around $376.45 per share.
• Stryker recently announced a quarterly dividend of $0.84 per share, with a payout ratio of 44.50%, indicating a dividend yield of 0.9%.

AAFMAA Wealth Management & Trust LLC cut its stake in Stryker Corporation (NYSE:SYK - Free Report) by 15.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,634 shares of the medical technology company's stock after selling 852 shares during the quarter. AAFMAA Wealth Management & Trust LLC's holdings in Stryker were worth $1,833,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Goodman Advisory Group LLC acquired a new position in shares of Stryker in the first quarter valued at approximately $32,000. City Holding Co. boosted its stake in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC grew its holdings in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new position in Stryker during the 1st quarter worth $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the first quarter worth $40,000. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Stock Down 0.7%

NYSE SYK opened at $368.64 on Friday. The business has a fifty day moving average price of $386.11 and a two-hundred day moving average price of $378.95. The stock has a market capitalization of $140.93 billion, a PE ratio of 48.83, a PEG ratio of 2.68 and a beta of 0.93. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Wall Street Analyst Weigh In

Several research firms recently commented on SYK. Rothschild Redb upgraded shares of Stryker to a "hold" rating in a research note on Thursday, September 18th. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday, September 18th. They set a "neutral" rating and a $420.00 target price on the stock. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Evercore ISI boosted their price target on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Fourteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $430.33.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.